Clinical evaluation of pregnant women with SARS-COV2 pneumonia: a real-life study from Egypt

Samy Zaky 1, Hossam Hosny 2, Gehan Ellassal 3, Noha Asem 4, Amin Abdel Baki 5, Ehab Kamal 6, Akram Abdelbary 7, Ahmad Said 7, Hamdy Ibrahim 8, Khaled Taema 7, Wagdy Amin 9, Sherief Abd-Elsalam 10*, Shaimaa Soliman 11, Hend Salah Abdelmenam 12, Ahmed S. Mohamed 13, Mohamed Elnady 14, Mohamed Hassany 5 and Hala Zaid 9

Abstract

Background: Knowledge about the outcome of COVID-19 on pregnant women is so important. The published literature on the outcomes of pregnant women with COVID-19 is confusing. The aim of this study was to report our clinical experience about the effect of COVID-19 on pregnant women and to determine whether it was associated with increased mortality or an increase in the need for mechanical ventilation in this special category of patients.

Methods: This was a cohort study from some isolation hospitals of the Ministry of Health and Population, in eleven governorates, Egypt. The clinical data from the first 64 pregnant women with COVID-19 whose care was managed at some of the Egyptian hospitals from 14 March to 14 June 2020 as well as 114 non-pregnant women with COVID-19 was reviewed.

Results: The two groups did not show any significant difference regarding the main outcomes of the disease. Two cases in each group needed mechanical ventilation \( (p = 0.617) \). Three cases (4.7%) died among the pregnant women and two (1.8%) died among the non-pregnant women \( (p = 0.352) \).

Conclusions: The main clinical outcomes of COVID-19 were not different between pregnant and non-pregnant women with COVID-19. Based on our findings, pregnancy did not exacerbate the course or mortality of COVID-19 pneumonia.

Keywords: COVID-19, Pregnancy, Outcomes, Mortality, Egypt, Ventilation

1 Introduction

The virus that causes COVID-19 and the virus that caused the severe acute respiratory syndrome (SARS) outbreak in 2003 are genetically related to each other, but the diseases caused by them are completely different. SARS was more deadly but much less contagious than COVID-19 \([1, 2]\). COVID-19 is clinically milder than MERS or SARS in terms of severity and mortality (the death rate for COVID-19 appears to be around 2–5% \([1–4]\)).

As cases of COVID-19 continue to rise in countries across the region, health systems face tremendous pressure to manage COVID-19 patients \([1–8]\).

The published literature on the outcomes of pregnant women with COVID-19 is very confusing \([6–17]\). As of 20 April 2020, 51 papers have reported primary data on COVID-19 during pregnancy \([6–32]\). However, there were a lot of problems with these information sources. First, there was double counting of cases. This was a particular problem with early reports from China, and the authors rarely explained it. Second, most of the reports were of very small numbers; meanwhile, the larger studies reported few details. Another problem was that
one third of these papers were individual case reports, which were likely biased toward severe or conditions without classical presentation.

Pregnant women are particularly vulnerable to respiratory pathogens and acute pneumonia, because they are in an immunosuppressed state, and additionally the adaptive physiological changes during pregnancy make them intolerant to hypoxia [25, 26]. The aim of this study is to clinically evaluate the effect of COVID-19 on pregnant women and to determine whether it was associated with increased mortality or need for mechanical ventilation in this special category of patients.

2 Methods
2.1 Study design and settings
This was a cohort study from some isolation hospitals affiliated to the Ministry of Health and Population in 11 governorates in Egypt. We reviewed clinical data from the first 64 pregnant women with COVID-19 whose care was managed at these Egyptian hospitals from 14 March to 14 June 2020 as well as 114 non-pregnant women with COVID-19.

2.2 Data collection methods
All pregnant females were subjected to full history taking, clinical examination, and full-laboratory data.

The main outcomes were the difference in mortality rates and the need for mechanical ventilation.

The research was approved by the Ministry of Health and Population Research Ethics Committee. An informed consent was obtained from all participants in this research. Privacy of participants and confidentiality of the data were assured. Risks and Benefits were declared.

2.3 Statistical analysis
Data were expressed in number (No.), percentage (%), mean (X), and standard deviation (SD). Student’s t test was used for comparison of quantitative normally distributed variables between two groups, while Mann–Whitney’s test was used for not normally distributed ones. Chi-square test (χ2) was used to study association between qualitative variables. Whenever any of the expected cells were less than five, Fisher’s exact test was used. A univariate logistic regression analysis was performed to ascertain the effects of possible risk factors on the final outcome. Two-sided P value of < 0.05 was considered statistically significant.

3 Results
The study included 64 pregnant women with mean gestational age of 10.73 ± 2.15 weeks. The mean age of the pregnant women was 34.93 ± 6.27 years with no significant difference from the non-pregnant group (p = 0.109). Among the pregnant COVID-19 patients, 9 (14.1) were in the first, 16 (25.0) in the second and 39 (60.9) in the third trimester. Four (6.25%) of the pregnant group had hypertension, 3 (4.7%) had diabetes mellitus and 4 (6.25%) had other comorbidities including cancer, asthma, and rheumatic heart disease. There was no significant difference between the 2 groups regarding different comorbidities, percentage of oxygen saturation at presentation or disease severity (p = 0.700, 0.206, and 0.363 respectively) (Table 1).

The laboratory investigation did not show any significant difference between the two groups (Table 2).

The two groups did not show any significant difference regarding the main outcomes of the disease. Two cases in each group needed mechanical ventilation (p = 0.617). Three cases (4.7%) died among the pregnant women and two (1.8%) died among the non-pregnant women (p = 0.352), (Table 3)

The univariate analysis showed that none of the possible risk factors was associated with the mortality among the studied patients including pregnancy (Table 4).

No statistically significant difference was noted among patients in different trimesters regarding the disease severity (p = 0.552). Four cases had severe COVID-19

| Table 1 Comparison between the pregnant COVID-19 and non-pregnant COVID-19 patients regarding their clinical characteristics, Egypt, 2020 |
|-----------------|-----------------|-----------------|--------|
| Variable | Pregnant COVID-19 (n = 64) | Non-pregnant COVID-19 (n = 114) | P value |
| Age (in years) | 34.93 ± 6.27 | 36.91 ± 8.60 | 0.109 |
| Trimester | | | |
| First | 9 (14.1) | – | – |
| Second | 16 (25.0) | | |
| Third | 39 (60.9) | | |
| Co-morbidities | | | |
| No | 53 (82.8) | 88 (77.2) | 0.700 |
| HTN | 4 (6.25) | 11 (9.6) | |
| DM | 3 (4.7) | 9 (7.9) | |
| Others | 4 (6.25) | 6 (5.3) | |
| O2 saturation | | | |
| 100–95% | 50 (78.1) | 74 (64.9) | 0.206 |
| 95–90% | 6 (9.4) | 23 (20.2) | |
| 90–85% | 5 (7.8) | 8 (7.0) | |
| < 85% | 3 (4.7) | 9 (7.9) | |
| Disease severity | | | |
| Mild | 44 (68.8) | 75 (65.8) | |
| Moderate | 16 (25.0) | 36 (31.6) | 0.363 |
| Severe | 4 (6.2) | 3 (2.6) | |

HTN hypertension, DM diabetes mellitus
infection; they were all in the 3rd trimester. No severe cases were reported in the 1st or 2nd trimesters. Although all the maternal deaths occurred in the 3rd trimester, this was not statistically significant \( (p = 0.715) \) (Table 5).

Among all the pregnant patients, two cases (3.1%) had intrauterine fetal death (IUFD), one baby was born with hydrocephalus (1.6%) and one (1.6%) was born pre-term. There was no significant association between the trimester and the fetal outcome \( (p = 0.406) \) (Table 5).

### Discussion

This study included 64 pregnant women with mean gestational age of 10.73 ± 2.15 weeks. There was no significant difference between the 2 groups regarding different comorbidities or percentage of oxygen saturation at presentation \( (p = 0.700 \text{ and } 0.206 \text{ respectively}) \). So, both groups were not significantly different regarding the baseline demographic criteria or regarding the presence of comorbid diseases.

#### Table 2
Comparison between the pregnant COVID-19 and non-pregnant COVID-19 patients regarding their laboratory characteristics, Egypt, 2020

| Variable | Pregnant COVID \( (n = 64) \) Mean ± SD | Non-pregnant COVID \( (n = 114) \) Mean ± SD | \( P \text{ value} \) |
|----------|------------------------------------------|------------------------------------------|------------------|
| Hb       | 10.73 ± 2.15                             | 11.23 ± 1.54                             | 0.125            |
| WBCs     | 7.34 ± 3.11                              | 6.59 ± 3.01                              | 0.116            |
| Lymphocytes | 11.13 ± 14.65                      | 11.94 ± 9.32                             | 0.653            |
| Neutrophils | 76.25 ± 152.69                      | 74.89 ± 139.34                           | 0.951            |
| Platelets | 245.42 ± 114.78                      | 238.17 ± 121.0                           | 0.696            |
| CRP      | 16.67 ± 27.06                           | 24.15 ± 31.52                            | 0.085            |
| ALT      | 26.25 ± 53.51                           | 29.60 ± 49.23                            | 0.673            |
| AST      | 29.08 ± 43.88                           | 28.00 ± 14.66                            | 0.131            |
| Creatinine | 0.68 ± 0.46                           | 0.82 ± 1.09                              | 0.664            |
| Albumin  | 3.17 ± 6.87                             | 3.24 ± 5.18                              | 0.938            |
| D dimer  | 21.06 ± 117.49                          | 46.42 ± 241.15                           | 0.285            |
| Serum ferritin | 320.85 ± 223.32          | 360.78 ± 509.82                          | 0.186            |

Interestingly, the two groups did not show any significant difference regarding the main outcomes of the disease. These results indicate that the main clinical outcomes of COVID-19 were not different between pregnant and non-pregnant women with COVID-19.

The National Institute of Health (NIH) (2020) reported that surveillance data released by the CDC in June 2020 showed that COVID-19-related death rates were similar in the pregnant and non-pregnant populations. Pregnancy outcomes such as preterm birth or pregnancy loss were not evaluated [28]. This report agrees with our conclusion that the mortality risks were similar among pregnant and non-pregnant women with COVID-19 infection.

On the other side, an Iranian case series reported maternal deaths in seven pregnant women among nine pregnant women who were infected with the novel coronavirus [29]. This was extremely different from our study.

### Table 3
Comparison between the pregnant COVID-19 and non-pregnant COVID-19 patients regarding the main clinical disease-outcomes, Egypt, 2020

| Variable              | Pregnant COVID \( (n = 64) \) No. (%) | Non-pregnant COVID \( (n = 114) \) No. (%) | \( P \text{ value} \) |
|-----------------------|--------------------------------------|------------------------------------------|------------------|
| Need for mechanical ventilation | 2 (3.2)                      | 2 (1.8)                                  | 0.617            |
| Mortality             |                                      |                                          |                  |
| Died                  | 3 (4.7)                              | 2 (1.8)                                  | 0.352            |
| Survived              | 61 (95.3)                             | 112 (98.2)                                |                  |

### Table 4
Univariate analysis of possible risk factors associated with patients’ mortality in the studied groups, Egypt, 2020

| Factor | Univariate analysis |
|--------|---------------------|
|        | \( P \text{ value} \) | OR | 95% CI |
| Age    | 0.425               | 0.953 | 0.846 | 1.073 |
| O2 saturation | 0.779 | 1.174 | 0.383 | 3.600 |
| ALT    | 0.904               | 1.002 | 0.969 | 1.036 |
| Creatinine | 0.830 | 1.249 | 0.163 | 9.580 |
| Ferritin | 0.341 | 1.100 | 0.997 | 1.009 |
| CRP    | 0.074               | 0.977 | 0.953 | 1.002 |
| D dimer | 0.987 | –     | –     | –     |
| Presence of comorbidity | 0.731 | 0.676 | 0.073 | 6.296 |
| Pregnancy | 0.274 | 0.363 | 0.059 | 2.23  |

### Table 5
Maternofetal clinical features and outcome among different trimesters, Egypt, 2020

| Clinical feature | 1st trimester \( (n = 9) \) No. (%) | 2nd trimester \( (n = 16) \) No. (%) | 3rd trimester \( (n = 39) \) No. (%) | \( P \text{ value} \) |
|-----------------|------------------------------------|------------------------------------|------------------------------------|------------------|
| Disease severity |                                    |                                    |                                    |                  |
| Mild            | 7 (77.8)                           | 11 (68.8)                          | 26 (66.6)                          | 0.552            |
| Moderate        | 2 (22.2)                           | 5 (31.2)                           | 9 (23.1)                           |                  |
| Severe          | 0 (0.0)                            | 0 (0.0)                            | 4 (10.3)                           |                  |
| Maternal deaths |                                    |                                    |                                    |                  |
| IUFD            | 1 (11.1)                           | 0 (0.0)                            | 1 (2.6)                            | 0.406            |
| Hydrocephalus   | 0 (0.0)                            | 1 (6.3)                            | 0 (0.0)                            |                  |
| Preterm labor   | 0 (0.0)                            | 1 (6.3)                            | 0 (0.0)                            |                  |
findings. However, and generally speaking, individual case reports were likely biased toward severe or unusual disease.

4.1 Limitations of the study
The main limitation of the study is the short time of the outcome, therefore, further studies about the long-term outcomes for the newborn and whether mother-to-child transmission are required. Nevertheless, the data in this study allow for better understanding of the clinical outcomes of COVID-19 infection in pregnancy and whether they were different between pregnant and non-pregnant females. Further studies discussing the follow-up of recovered pregnant women and the impact on their babies, type of delivery, and puerperium are highly recommended.

5 Conclusions
The main clinical outcomes of COVID-19 were not different between pregnant and non-pregnant women with COVID-19. Based on our findings, pregnancy did not exacerbate the course or mortality of COVID-19 pneumonia.

Acknowledgements
The authors acknowledge all patients who participated in this study and take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

Authors’ contributions
SZ, SA-E, and HZ designed the study. NA and SS developed the methodology. SZ and SA-E wrote the manuscript. SZ, HH, GE, NA, AAB, FK, AA, AS, HI, KT, WA, SA-E, HSA, ASM, ME, and MH collected the data. All the authors participated sufficiently in the work, read, and approved the final version of the manuscript.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials
Data will be available from the authors on reasonable request.

Declarations
Ethics approval and consent to participate
The research was approved by the Research Ethics Committee of Tanta University, Faculty of Medicine with approval code 53966/7/20. The research was also approved by the Research Ethics Committee of the Ministry of Health and Population. An informed written consent was obtained from each patient. The study protocol complies with the ethical guidelines of the 1975 Declaration of Helsinki as reflected in prior approval by the institution’s Human Research Committee.

Consent for publication
Not applicable.

Competing interests
The authors declare that there is no conflict of interest.

Author details
1Hepatogastroenterology and Infectious Diseases Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. 2Chest Diseases Department, Head of Pulmonary Hypertension Unit, Faculty of Medicine, Cairo University, Cairo, Egypt. 3Pulmonary Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 4Public Health Department, Faculty of Medicine, Cairo University, Cairo, Egypt. 5National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt. 6Tropical Medicine Department. Medical Division, National Research Center, Cairo, Egypt. 7Critical Care Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt. 8Fever Hospitals, Ministry of Health and Population (MOHP), Cairo, Egypt. 9MOHP, Cairo, Egypt. 10Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt. 11Public Health and Community Medicine Department, Menoufia University, Menoufia, Egypt. 12Obstetrics and Gynecology Department, Al Zahraa University Hospital, Cairo, Egypt. 13Chest Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt. 14Pulmonology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.

Received: 2 December 2020 Accepted: 18 October 2021
Published online: 04 November 2021

References
1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. https://doi.org/10.1016/S0140-6736(20)30211-7.
2. World Health Organization. Infection prevention and control during health care when COVID-19 is suspected. 2020. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 19 Mar 2020.
3. Bootsma MC, Ferguson NM. The effect of public health measures on the 1918 influenza pandemic in U.S. cities. Proc Natl Acad Sci USA. 2007;104(18):7588–93. https://doi.org/10.1073/pnas.0701171104.
4. Desouky E. Prediction of the epidemic peak of Covid19 in Egypt. medRxiv. 2020;2020.04.30.20086751. https://doi.org/10.1101/2020.04.30.20086751.
5. Pastick KA, Nicol MR, Smyth E, Zaid R, Bouivate DR, Rajasingham R, et al. A systematic review of treatment and outcomes of pregnant women with COVID-19: a call for clinical trials. Open Forum Infect Dis. 2020;7:ofaa350. https://doi.org/10.1093/ofid/ofaa350.
6. Khalil A, Kalafat E, Beniloug C, O’Brien P, Morris E, Draycott T, et al. SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes. EClin Med. 2020;25:100446. https://doi.org/10.1016/j.eclinm.2020.100446.
7. Wenling Y, Junacho Q, Xiao Z, Ouyang S. Pregnancy and COVID-19: management and challenges. Res Int Med Trop Sao Paulo. 2020;62:e62. https://doi.org/10.1590/s1678-9946202002602.
8. Liu F, Liu H, Hou L, Li J, Zheng H, Chi R, et al. Clinico-radiological features and outcomes in pregnant women with COVID-19 pneumonia compared with age-matched non-pregnant women. Infect Drug Resist. 2020;13:2845–54. https://doi.org/10.2147/IDR.S264591.
9. Ronije L, Lansberg JK, Våhareva Ø, Hansson SR, Herbst A, Zaitcham M. Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery. BMC Pregnancy Childbirth. 2020;20(1):511. https://doi.org/10.1186/s12884-020-03172-y.
10. Borges do Nascimento IJ, von Grotee TC, O’Mathúna DP, Abduljazeem HM, Henderson C, Jayarajah U, et al. Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: a systematic review and series of meta-analyses. PLoS One. 2020;15(9):e0239235. https://doi.org/10.1371/journal.pone.0239235.
11. Tug N, Yassa M, Köle E, Sakin Ö, Cakr Köle M, Karateke A, et al. Pregnancy worsens the morbidity of COVID-19 and this effect becomes more prominent as pregnancy advances. Turk J Obstet Gynecol. 2020;17(3):149–54. https://doi.org/10.4274/tjogalenos.2020.38924.
12. Han Y, Ma H, Sun M, Han F, Wang F, Ji J, et al. Clinical manifestation, outcomes in pregnant women with COVID-19 and the possibility of vertical transmission: a systematic review of the current data. J Perinat Med. 2020;48(9):912–24. https://doi.org/10.1515/jpm-2020-0431.
13. Afshar Y, Gaw SL, Flaherman VJ, Chambers BD, Krakow D, Berghella V, et al. Clinical presentation of Coronavirus disease 2019 (COVID-19) in pregnant
and recently pregnant people. Obstet Gynecol. 2020;136(5):1117–25. https://doi.org/10.1097/AOG.0000000000004178.

14. Simsek Y, Ciplak B, Songur S, Kara M, Karahocagil MK. Maternal and fetal outcomes of COVID-19, SARS, and MERS: a narrative review on the current knowledge. Eur Rev Med Pharmacol Sci. 2020;24(18):9748–52. https://doi.org/10.26355/eurrev_202009_23608.

15. Menezes MO, Takekoto M, Nakamura-Pereira M, Katz L, Amorim MMR, Salgado HO, et al. Risk factors for adverse outcomes among pregnant and postpartum women with acute respiratory distress syndrome due to COVID-19 in Brazil. Int J Gynaecol Obstet. 2020;151(3):415–23. https://doi.org/10.1016/j.ijgo.2013.04.017.

16. Figueiro-Filho EA, Yudin M, Farine D. COVID-19 during pregnancy: an overview of maternal characteristics, clinical symptoms, maternal and neonatal outcomes of 10,096 cases described in 15 countries. J Perinat Med. 2020;48(9):900–11. https://doi.org/10.1515/jpm-2020-0364 PMID: 33001856.

17. Alay I, Yıldız S, Kaya C, Yasar KK, Aydin OA, Karaosmanoglu HK, et al. The clinical findings and outcomes of symptomatic pregnant women diagnosed with or suspected of having coronavirus disease 2019 in a tertiary pandemic hospital in Istanbul, Turkey. J Obstet Gynaecol Res. 2020. https://doi.org/10.1111/jog.14493.

18. Marín Gabriel MA, Reyne Vergeli M, Caserío Carbonero S, Sole L, Carriósa Molina T, Rivero Calle I, et al. Maternal, perinatal and neonatal outcomes with COVID-19: a multicenter study of 242 pregnancies and their 248 infant newborns during their first month of life. Pediatr Infect Dis J. 2020;39(12):e393. https://doi.org/10.1097/INF.0000000000002902.

19. Li W, Yu N, Kang Q, Zeng W, Deng D, Chen S, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. https://doi.org/10.1136/bmj.m3320.

20. Pirjani R, Hosseini R, Soori T, Rabiei M, Hosseini L, Abiri A, et al. Maternal and neonatal outcomes in COVID-19 infected pregnancies: a prospective cohort study. J Travel Med. 2020;27(7):taaa158. https://doi.org/10.1093/jtm/taaa158.

21. Diriba K, Awulachew E, Getu E. The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis. Eur J Med Res. 2020;25(1):39. https://doi.org/10.1186/s40001-020-00439-w.

22. Allooty J, Stallings E, Bonet M, Yaprak C, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: a retrospective review of medical records. Lancet. 2020;395(10226):809–15. https://doi.org/10.1016/S0140-6736(20)30360-3 Erratum in: Lancet. 2020 Mar 28; 395(10229):1038. Erratum in: Lancet. 2020 Mar 28; 395(10229):1038.

23. Kucirka LM, Norton A, Sheffield JS. Severity of COVID-19 in pregnancy: a review of current evidence. Am J Reprod Immunol. 2020;84(5):e13340. https://doi.org/10.1111/aji.13340.

24. Pirjani R, Kosaei M, Soori T, Rabiei M, Hosseini L, Abiri A, et al. Maternal and neonatal outcomes with COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175(8):817–26. https://doi.org/10.1001/jamapediatrics.2021.1050.

25. Santhosh J, Al Salmani M, Khansie F, Ali Al Ubaidani S, Al-Zakwani I. Clinical characteristics of COVID-19 in pregnant women: a retrospective descriptive single-center study from a tertiary hospital in Muscat, Oman. Int J Gynaecol Obstet. 2021;152(2):270–4. https://doi.org/10.1016/j.ijgo.2021.03.014.

26. Papageorgiou AT, Denuelle F, Guiner RB, Rauch S, Garcia-May PK, Mhatre M, et al. Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study. Am J Obstet Gynecol. 2021;225(3):289.e1–e17. https://doi.org/10.1016/j.ajog.2021.05.014.

27. Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Khollin A, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175(8):817–26. https://doi.org/10.1001/jamapediatrics.2021.1050.